Marked Expansion of Exocrine and Endocrine Pancreas With Incretin Therapy in Humans With Increased Exocrine Pancreas Dysplasia and the Potential for Glucagon-Producing Neuroendocrine Tumors

(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)

Click on image to view larger version.

FIG. 2.
FIG. 2.

Glucagon immunohistochemistry in pancreas in DM after incretin therapy. A–E: Sections of pancreas from DM-I donors (cases 6185, 6186, 6206, and 6203 with sitagliptin) immunostained for glucagon (pink) with hematoxylin counterstain. Exuberant expansion of glucagon immunoreactive cells is seen as enlarged eccentrically shaped islets as well as nodular and linear aggregates of cells intimately associated with ducts and demonstrating variable extension into duct lumens (arrow). C–E: Higher-power images show glucagon immunoreactivity in cells lining ducts. F–I: Pancreas sections from DM-I donors (case 6199, sitagliptin; 6189, exenatide) show immunofluorescent costaining for cytokeratin (green), glucagon (red), and DAPI nuclear counterstain (blue). Glucagon-expressing cells are present within and adjacent to keratin-positive duct structures. G: One cell costaining for cytokeratin and glucagon is indicated by the arrow.

This Article

  1. Diabetes vol. 62 no. 7 2595-2604
  1. Free via Open Access: OA
  2. Supplementary Data